Several ongoing trials are evaluating the efficacy of ziftomenib treatment combinations in this acute myeloid leukemia population.
Ghayas C. Issa, MD, MS
Advertisement
Articles by Ghayas C. Issa, MD, MS
Single-agent ziftomenib achieved an ORR of 35% in patients with relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.
New targeted therapies are needed to improve outcomes for patients with NPM1-mutant relapsed/refractory acute myeloid leukemia.
Advertisement
Latest Updated Articles
Why Evaluate Single-Agent Ziftomenib in NPM1+ R/R Acute Myeloid Leukemia?Published: September 13th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
2
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
3
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
4
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
5
